EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE
Peakefavirenz; lamivudine; tenofovir disoproxil fumarate
NDAORALTABLET
Approved
Aug 2018
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE (efavirenz; lamivudine; tenofovir disoproxil fumarate) by Aurobindo Pharma is fixed-dose combination of antiviral drugs efv, 3tc, and tdf with antiviral activity against hiv-1 [see ]. First approved in 2018.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
This is a fixed-dose combination tablet containing efavirenz, lamivudine, and tenofovir disoproxil fumarate—three antiretroviral agents with complementary mechanisms against HIV-1. The combination provides a simplified, single-tablet regimen for HIV treatment. It is designed for patients requiring first-line or maintenance antiretroviral therapy.
Peak
Product is at peak market maturity with moderate competitive pressure (30%); commercial teams are focused on market share defense and compliance support rather than expansion.
Mechanism of Action
fixed-dose combination of antiviral drugs EFV, 3TC, and TDF with antiviral activity against HIV-1 [see ].
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on this product offers stability in a mature, established therapeutic area with predictable market dynamics and strong compliance/reimbursement infrastructure. However, limited clinical innovation and zero linked job postings suggest modest team growth and potential for role consolidation as competitive pressures increase.
Brand ManagerMedical Science Liaison
Worked on EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.